The Food and Drug Administration (FDA) has approved a new blood test for Alzheimer’s disease, marking the fourth such diagnostic tool to receive clearance in less than two years. Roche announced on Sunday that its Elecsys Phospho-Tau blood test received approval for use in diagnosing the condition. This follows the first FDA approval of a similar blood-based diagnostic test in May 2025.
Developed in partnership with Eli Lilly, the test is designed for adults aged 55 and older who exhibit signs, symptoms, or complaints of cognitive decline. According to Roche, the test is intended to assist physicians in identifying patients who may require earlier evaluation. The Alzheimer’s Association noted in a Monday statement that while no single test can diagnose the disease on its own, this approval provides clinicians with an additional validated tool for patient evaluation.
Alzheimer’s disease has traditionally been diagnosed using a combination of cognitive testing, brain scans, and the exclusion of other medical conditions that affect memory and cognition. Roche stated that the Elecsys pTau217 is the first single-biomarker blood test cleared by the FDA to support both "rule-in and rule-out" assessments of amyloid pathology, a hallmark of Alzheimer’s disease.
For the millions of Americans navigating cognitive symptoms, the introduction of this test means they may receive an earlier assessment during primary or specialty care visits. Instead of relying solely on cognitive interviews or expensive imaging, a person would notice a standard blood draw being used to screen for biomarkers of the disease. Roche Diagnostics North America CEO Dan Malarek stated the test could change how the disease is assessed in both primary and specialty care settings, though the specific out-of-pocket cost per patient was not reported.
The approval sets a precedent for the use of single-biomarker blood tests in clinical settings, which may influence future policy regarding how Alzheimer’s screenings are integrated into routine healthcare. The Alzheimer's Association indicated that these developments allow for the new tests to be incorporated with existing standard evaluation methods. While the FDA has granted the clearance, the source did not provide a specific date for when the test will be widely available in clinics or hospitals. Continuing research and clinical implementation will determine the long-term impact on diagnostic accuracy and patient outcomes.